Table 3.
Characteristics of FH subjects affected by SARS-CoV-2.
| SARS-CoV-2 FH (n = 19) | |
|---|---|
| Demographic Characteristics | |
| Age, years | 58.7 ± 5.18 |
| Male, n (%) | 10 (52.6) |
| Body mass index, kg/m2 | 26.1 ± 1.52 |
| ASCVD, n (%) | 15 (78.9) |
| FH Phenotype | |
| Heterozygote, n (%) | 15 (78.8) |
| Double heterozygote, n (%) | 1 (5.3) |
| Compound heterozygote, n (%) | 2 (10.6) |
| Homozygote, n (%) | 1 (5.3) |
| Lipid Profile Before Lockdown | |
| TC, mg/dL | 162.45 ± 10.24 |
| HDL-C, mg/dL | 49.8 ± 10.13 |
| TG, mg/dL | 97.25 (66.0–113.5) |
| LDL-C, mg/dL | 93.34 ± 10.11 |
| Non-HDL-C, mg/dL | 113.36 ± 10.43 |
| LDL-C target, n (%) | 8 (42.1) |
| Risk Factors | |
| Type 2 diabetes, n (%) | 3 (15.8) |
| Hypertension, n (%) | 16 (84.2) |
| Smokers, n (%) | 7 (36.8) |
| ≥2 risk factors, n (%) | 10 (52.6) |
| Treatments | |
| High-intensity statin, n (%) | 17 (89.5) |
| Moderate-intensity statin, n (%) | 2 (10.5) |
| Low-intensity statin, n (%) | - |
| Statin intolerant, n (%) | - |
| Ezetimibe, n (%) | 19 (100) |
| PCSK9 inhibitor, n (%) | 12 (63.2) |
| Statin + ezetimibe + PCSK9 inhibitor, n (%) | 12 (63.2) |
| Antiplatelet therapy, n (%) | 15 (78.9) |
Data are presented as mean ± standard deviation, percentages or median (interquartile range). FH = familial hypercholesterolemia, ASCVD = atherosclerotic cardiovascular disease, TC = total cholesterol, HDL-C = high-density lipoprotein cholesterol, TG = triglycerides, LDL-C = low-density lipoprotein cholesterol, PCSK9 = proprotein convertase subtilisin-kexin type 9.